Accrual issues in genitourinary cancer clinical trials

Urologic Oncology: Seminars and Original Investigations

Volumn 24, Issue 5, 2006, Pages 379-383

  Lara Jr , Primo N ^a   de Vere White, Ralph ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; PACLITAXEL; VINBLASTINE;

BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; HUMAN; KIDNEY CARCINOMA; NEPHRECTOMY; PRIORITY JOURNAL; PROSTATE CARCINOMA; UROGENITAL TRACT CANCER;

CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; HUMANS; PATIENT PARTICIPATION; PATIENT SELECTION; UROGENITAL NEOPLASMS;

EID: 33748155227     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2005.11.037     Document Type: Editorial

References (12)

1. Kaluzny A., Brawley O., Garson-Angert D., et al. Assuring access to state-of-the-art care for U.S. minority populations: The first 2 years of Minority-Based Community Clinical Oncology Program. J Natl Cancer Inst 85 (1993) 1945-1950
2. Tejeda H.A., Green S.B., Trimble E.L., et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute treatment trials. J Natl Cancer Inst 88 (1996) 812-816
3. National Children's Cancer Foundation Web site. Childhood cancer facts (2005). http://www.nccf.org/ Available at: http://www.nccf.org/. Accessed April 12.
4. Kolata G, Eichewald K. In pediatrics, a lesson in making use of experimental procedures. The New York Times (Sunday). October 3, 1999.
5. Sateren W.B., Trimble E.L., Abrams J., et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 20 (2002) 2109-2117
6. Ehrlich P.F., Newman K.D., Haase G.M., et al. Lessons learned from a failed multi-institutional randomized controlled study. J Pediatr Surg 37 (2002) 431-436
7. Haidich A.B., and Ioannidis J.P. Effect of early patient enrollment on the time to completion and publication of randomized controlled trials. Am J Epidemiol 154 (2001) 873-880
8. Lara Jr. P.N., Higdon R., Lim N., et al. Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment. J Clin Oncol 19 (2001) 1728-1733
9. Grossman H.B., Natale R.B., Tangen C.M., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349 (2003) 859-866
10. Flanigan R.C., Salmon S.E., Blumenstein B.A., et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345 (2001) 1655-1659
11. Millikan R., Dinney C., Swanson D., et al. Integrated therapy for locally advanced bladder cancer: Final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 19 (2001) 4005-4013
12. Herr H.W., Faulkner J.R., and Grossman H.B. Surgical factors influence bladder cancer outcomes: A cooperative group report. J Clin Oncol 22 (2004) 2781-2789